3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Neoplasms
27
Colorectal Neoplasms
20
Breast Neoplasms
16
Ovarian Neoplasms
15
Pancreatic Neoplasms
13
Neoplasm Metastasis
12
Lung Neoplasms
11
Stomach Neoplasms
10
Leukemia, Myeloid, Acute
10
Melanoma
9
Lymphoma, Non-Hodgkin
8
Small Cell Lung Carcinoma
6
Recurrence
6
Liver Neoplasms
6
Leukemia
6
Head and Neck Neoplasms
6
Fallopian Tube Neoplasms
6
Prostatic Neoplasms
5
Glioblastoma
5
Cholangiocarcinoma
5
Adenocarcinoma
5
Urinary Bladder Neoplasms
4
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Sarcoma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
4
Lymphoma
4
Gastrointestinal Neoplasms
4
Uterine Cervical Neoplasms
3
Interventions
Rituximab
43
Cyclophosphamide
26
fludarabine
15
ibrutinib
14
Vincristine
11
Prednisone
11
Doxorubicin
11
pirtobrutinib
10
Bendamustine Hydrochloride
10
obinutuzumab
9
polatuzumab vedotin
6
Inotuzumab Ozogamicin
6
tocilizumab
5
pembrolizumab
5
glofitamab
5
Gemcitabine
5
zanubrutinib
4
venetoclax
4
ublituximab
4
Lenalidomide
4
Brentuximab Vedotin
4
Antigens, CD19
4
tazemetostat
3
acalabrutinib
3
Everolimus
3
DTRMWXHS-12
3
veltuzumab
2
sepantronium
2
iberdomide
2
denileukin diftitox
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, B-Cell
×
Drug Therapy
×
Clear all
NCT03570892
2026-05-14
BELINDA
Novartis
Phase 3
Completed
330 enrolled
10 charts